The pharmaceutical world is observing a significant shift in blood sugar treatment with the introduction of GLP-1 skin applications. These systems offer a seemingly more user-friendly alternative to shots of GLP-1 receptor agonists, minimizing the frequency of daily needle pricks. The technology releases the compound directly through the epidermis,